Get the Stockscreener App
82.72
2.68%
-2.28
After Hours:
82.86
0.14
+0.17%
Apogee Therapeutics Inc stock is traded at $82.72, with a volume of 788.95K.
It is down -2.68% in the last 24 hours and down -0.37% over the past month.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$85.00
Open:
$84.88
24h Volume:
788.95K
Relative Volume:
0.83
Market Cap:
$6.24B
Revenue:
-
Net Income/Loss:
$-274.62M
P/E Ratio:
-19.11
EPS:
-4.3278
Net Cash Flow:
$-235.37M
1W Performance:
-1.75%
1M Performance:
-0.37%
6M Performance:
+8.76%
1Y Performance:
+96.86%
1-Day Range:
$81.59
$87.43
1-Week Range:
$81.04
$91.90
52-Week Range:
$34.34
$95.31
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
82.72 | 6.41B | 0 | -274.62M | -235.37M | -4.3278 |
VRTX
Vertex Pharmaceuticals Inc
|
435.71 | 113.14B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
601.65 | 64.60B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.18 | 54.97B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.22 | 39.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.19 | 31.79B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Hold |
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Behavioral Patterns of APGE and Institutional Flows - Stock Traders Daily
APGE Maintained by RBC Capital -- Price Target Raised to $97.00 - GuruFocus
RBC Raises Price Target on Apogee Therapeutics to $97 From $82, Keeps Sector Perform, Speculative Risk - marketscreener.com
RBC Capital raises Apogee Therapeutics stock price target to $97 By Investing.com - Investing.com Nigeria
RBC Capital raises Apogee Therapeutics stock price target to $97 - Investing.com
Apogee Therapeutics CMO Dambkowski sells $432,904 in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics CMO Dambkowski sells $432,904 in stock - Investing.com
Apogee Therapeutics (APGE) CMO trades stock under Rule 10b5-1 plan - Stock Titan
Blackstone pledges $1.3 billion to help develop Apogee skin drug - MSN
Apogee (APGE) Secures Up to $1.3B in Non-Dilutive Financing from Blackstone to Advance Zumilokibart - Insider Monkey
These 10 mid-cap US healthcare companies carry the market's most expensive valuations - MSN
APGE Stock Price, Quote & Chart - ChartMill
Should Positive Phase 2 Zumilokibart Data and Blackstone Funding Reshape the Outlook for Apogee Therapeutics (APGE) Investors? - Sahm
Apogee Therapeutics readies Zumi for phase 3 with Blackstone backing - MSN
Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing - sharewise.com
APGE: Strong phase II-B results and a $1.3B Blackstone deal drive late-stage and combo program expansion - TradingView
Deutsche Bank Adjusts PT on Apogee Therapeutics to $116 From $118, Maintains Buy Rating - marketscreener.com
Apogee Therapeutics (APGE) Among Most Expensive U.S. Healthcare Stocks by Valuation - GuruFocus
These 10 mid-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 2 APEX Results For Zumilokibart - Yahoo Finance
Apogee Therapeutics shares surge following $1.3 billion Blackstone financing partnership (APOG) - MSN
Latham & Watkins Advises Apogee Therapeutics in US$1.3 Billion Strategic Financing Collaboration With Blackstone Life Sciences, One of the Largest Life Sciences Financings of 2026 - Legal Desire
Apogee falls following Phase 2 results for zumilokibart in atopic dermatitis - MSN
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic DermatitisSlideshow (NASDAQ:APGE) 2026-05-30 - Seeking Alpha
A Quick Look at Today's Ratings for Apogee Therapeutics(APGE.US), With a Forecast Between $81 to $131 - Moomoo
Analysts Offer Insights on Healthcare Companies: Agilent (A), Apogee Therapeutics (APGE) and Pfizer (PFE) - The Globe and Mail
(APGE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Apogee Stock in Focus After Blackstone Announces $1.3 Billion Deal - Bez Kabli
Apogee Therapeutics to Participate in Upcoming June Conferences - The Manila Times
Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing (APGE) - Seeking Alpha
Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program - Yahoo Finance
Hear Apogee Therapeutics' June fireside talks at Jefferies and Goldman - Stock Titan
Apogee Therapeutics Soars After $1.3B Deal with Blackstone Life Sciences - StockInvest.us
Transcript : Apogee Therapeutics, Inc.Special Call - marketscreener.com
Apogee Therapeutics Advances Eczema Drug Zumilokimab to Phase 3 Trials - geneonline.com
Blackstone backs Apogee’s atopic dermatitis therapy as it heads to Phase III - biocentury.com
Apogee Therapeutics and Blackstone Life Sciences Collaborate for $1.3 Billion to Advance Zumilokibart - geneonline.com
Apogee Therapeutics’ Phase 2 APEX Trial Assesses Zumilokibart Dosage Optimization for Atopic Dermatitis Over 16 Weeks - geneonline.com
APGE Maintained by Truist Securities -- Price Target Lowered to $81.00 - GuruFocus
Truist cuts Apogee Therapeutics stock price target on valuation By Investing.com - Investing.com South Africa
Apogee orbiting big AD market as Apex phase II data land - BioWorld News
Blackstone Backs Apogee With Up To $1.3 Billion - GuruFocus
Young biotech Apogee lands $1.3B deal that is called 'largest royalty financing' of its kind - The Business Journals
Latham Advises Apogee Therapeutics in Strategic Financing Collaboration - Latham & Watkins LLP
Apogee secures up to $1.3 billion from Blackstone to advance eczema drug - Reuters
Apogee Therapeutics (APGE) falls after new eczema trial data as investors digest results - Quiver Quantitative
Truist cuts Apogee Therapeutics stock price target on valuation - Investing.com
Apogee falls following phase 2 results for zumilokibart in atopic dermatitis - Seeking Alpha
Blackstone Life Sciences commits up to $1.3B to fund Waltham biotech's drug - The Business Journals
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.20%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):